This inventor holds 7 USPTO granted patents and 12 published patent applications, plus 2 CIPO patents and 4 EPO patents. Top assignees: Biontech Se, Tron—translationale Onkologie an Der Universitátsmedizin Der Johannes Gutenberg—universität Mainz Gemeinnützige Gmbh, Biontech Rna Pharmaceuticals Gmbh. Active years: 2019-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
4 out of 74 
3 out of 25 
2 out of 19 Years Active: 2019-2026
Title: **Lena Mareen Kranz: Pioneering Innovations in RNA Therapeutics**
Introduction
Lena Mareen Kranz is a distinguished inventor based in Mainz, Germany, whose contributions to the field of RNA technology have led to significant advancements in the treatment of autoimmune diseases and tumor immunotherapy. With a portfolio of three patents, she is recognized for her innovative approaches to leveraging RNA as therapeutic agents.
Latest Patents
Among Kranz’s latest patents are notable inventions that focus on non-immunogenic RNA for the treatment of autoimmune diseases. This invention is aimed at developing therapeutic agents that can induce tolerance towards autoantigens, thereby addressing the challenges posed by autoimmune disorders. Additionally, she has made strides in the field of immunotherapy with her patent for RNA formulations designed for delivering RNA to antigen-presenting cells, specifically dendritic cells (DCs) in the spleen. This formulation is pivotal for inducing immune responses after systemic administration of antigen-coding RNA, showcasing her commitment to groundbreaking research in immunotherapy.
Career Highlights
Throughout her career, Lena Mareen Kranz has collaborated with leading organizations, including BioNTech SE, where she contributed her expertise to innovative projects in the field of biotechnology. Her work at BioNTech SE has placed her at the forefront of RNA-based therapeutic advancements.
Collaborations
In her professional journey, Kranz has had the privilege of working alongside esteemed colleagues such as Ugur Sahin and Sebastian Kreiter. Their collaborations have undoubtedly enriched her research and expanded the potential applications of her inventions in the biomedical landscape.
Conclusion
Lena Mareen Kranz stands out as a leading figure in the realm of RNA innovations, with her patents paving the way for future therapies in autoimmune diseases and cancer treatment. Her dedication to research and collaboration embodies the spirit of innovation that drives progress in medical science. As she continues to explore new avenues in RNA technology, her contributions are sure to have a lasting impact on the field.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile